Skip to main content
Fig. 4 | Skeletal Muscle

Fig. 4

From: A mouse anti-myostatin antibody increases muscle mass and improves muscle strength and contractility in the mdx mouse model of Duchenne muscular dystrophy and its humanized equivalent, domagrozumab (PF-06252616), increases muscle volume in cynomolgus monkeys

Fig. 4

Effect of domagrozumab on skeletal muscle in cynomolgus monkeys. a Percent change in leg lean muscle mass over vehicle (PBS), measured by DXA, following 8 weeks of treatment with 10 and 30 mg/kg domagrozumab. b Myostatin levels in serum collected from all monkeys. c Percent change from baseline (start of study) in axial muscle volume after 8 weeks of treatment. d Percent change from baseline in appendicular muscle volume after 8 weeks of treatment. N = 5 animals for vehicle and 10 mg/kg groups and 3 animals for 30 mg/kg group. Data plotted are means ± SEM. * denotes p < 0.05 via ANOVA with Fisher’s LSD post-test versus vehicle; # denotes p < 0.05 versus 10 mg/kg domagrozumab; denotes time of dosing

Back to article page

Skeletal Muscle

ISSN: 2044-5040

Contact us